Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
May 17 2022 - 4:01PM
Business Wire
Regulatory News:
Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD)
(Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage
biotechnology company focused on the discovery and development of
chimeric antigen receptor T cell (CAR T) therapies for cancer,
today announced that the Company plans to participate virtually at
the upcoming H.C. Wainwright Global Investment Conference, May 23 –
26, 2022.
The Company’s presentation will be available on-demand through
the H.C. Wainwright conference portal, starting at 7 :00 a.m. EST
on Tuesday, May 24, 2022.
About Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company
focused on the discovery and development of chimeric antigen
receptor T cell (CAR T) therapies for cancer. The Company is
developing a pipeline of allogeneic (off-the-shelf) and autologous
(personalized) CAR T cell therapy candidates for the treatment of
both hematological malignancies and solid tumors. Celyad Oncology
was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and
New York, NY. The Company has received funding from the Walloon
Region (Belgium) to support the advancement of its CAR T cell
therapy programs. For more information, please visit www.celyad.com.
Forward-Looking Statement
This release contains forward-looking statements, within the
meaning of applicable securities laws, including the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements include, without limitation, statements
regarding: the CYAD-101-002 trial, including the clinical hold, the
timing and outcomes of additional data from Phase 1 IMMUNICY-1
trial of CYAD-211, safety and clinical activity of the product
candidates in Celyad Oncology’s pipeline, Celyad Oncology’s
financial condition and cash runway, and expected results of
operations and business outlook. The words “may,” “might,” “will,”
“could,” “would,” “should,” “plan,” “anticipate,” “intend,”
“believe,” “expect,” “estimate,” “future,” “potential,” “continue,”
“target” and similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking
statements are based on management's current expectations and may
involve known and unknown risks and uncertainties which might cause
actual results, financial condition, performance or achievements of
Celyad Oncology to differ materially from those expressed or
implied by such forward-looking statements. Such risk and
uncertainty includes, without limitation: the timing, duration and
outcome of the clinical hold on the CYAD-101-002 Phase 1b trial,
Celyad Oncology’s ability to continue to access to the equity
purchase agreement with Lincoln Park Capital Fund, LLC, our
financial and operating results, the duration and severity of the
COVID-19 pandemic, and global economic uncertainty, including with
respect to geopolitical conditions and attendant sanctions
resulting from the conflict in Ukraine. A further list and
description of these risks, uncertainties and other risks can be
found in Celyad Oncology’s U.S. Securities and Exchange Commission
(SEC) filings and reports, including in the latest Annual Report on
Form 20-F filed with the SEC, and subsequent filings and reports of
Celyad Oncology. These forward-looking statements speak only as of
the date of publication of this document and Celyad Oncology’s
actual results may differ materially from those expressed or
implied by these forward-looking statements. Celyad Oncology
expressly disclaims any obligation to update any forward-looking
statements in this document to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220517005686/en/
Investor and Media Contacts: Sara Zelkovic Communications
& Investor Relations Director Celyad Oncology investors@celyad.com
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Apr 2023 to Apr 2024